Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell Lymphoma
Elise A. Olsen(Durham Technical Community College), Jean Nichols(The University of Texas at San Antonio Health Science Center), Eric C. Vonderheid(Ashford and St Peter's Hospitals NHS Foundation Trust), James M. Reuben(The University of Texas MD Anderson Cancer Center), Patricia Bacha(The University of Texas at San Antonio Health Science Center), Kevin D. Cooper(University Hospitals of Cleveland), Fiona E. Craig(The University of Texas at San Antonio Health Science Center), Gary S. Wood(University of Wisconsin–Madison), David Fivenson(Trinity Health Ann Arbor Hospital), Elizabeth Knobler(The University of Texas at San Antonio Health Science Center), Allan R. Oseroff(Roswell Park Comprehensive Cancer Center), Ann Martin(The University of Texas at San Antonio Health Science Center), Lauren Pinter‐Brown(University of California, Irvine), Arthur E. Frankel(Cancer Institute of Florida), Peter Heald(Yale University), Francine M. Foss(Yale Cancer Center), Michael D. Gordon(The University of Texas at San Antonio Health Science Center), Arturo Molina(Janssen (United States)), Stanford J. Stewart(The University of Texas at San Antonio Health Science Center), Glen M. Bowen(The University of Texas at San Antonio Health Science Center), Seth R. Stevens(The University of Texas at San Antonio Health Science Center), Brian V. Jegasothy, Timothy M. Kuzel(Rush University), Michael Glodé(The University of Texas at San Antonio Health Science Center), Madeleine Duvic(Cancer Clinic)
Cited by 610
Related Papers
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k